Novartis will continue to do bolt-on deals and its capital allocation priorities remain unchanged, CEO Vasant Narasimhan said ...

Designation based on clinical evidence supporting potential of ianalumab in Sjögren’s disease, including phase III trials1Distinction expedites development and review of treatments for serious ...

Novartis has announced plans to construct a radioligand therapy (RLT) manufacturing facility in Winter Park, Florida, as part ...

As Novartis turns the calendar on a new year, the Swiss drugmaker is elaborating further on plans for the $23 billion U.S.

Zonsen PepLib Biotech Inc. ("PepLib") today announced that it has entered into a worldwide license agreement with Novartis for an undisclosed peptide-based asset in the field of radioligand therapies ...

Novartis will invest about $70M to build a Florida radioligand therapy plant, expanding its U.S. cancer drug manufacturing ...

Novartis AG (NYSE: NVS) released data on Thursday from the KALUMA Phase 3 study for the new malaria treatment KLU156 (ganaplacide/lumefantrine, or GanLum). GanLum is ...

Rhapsido helps to inhibit release of histamine and proinflammatory mediators by targeting BTK, offering unique approach to CSU treatment 1 Well-controlled disease observed as fast as two weeks, with ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — Novartis is paying $1 billion upfront in a licensing deal for an ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — Novartis on Tuesday increased its earnings guidance for the ...

GENEVA — Switzerland's medical products authority has granted the first approval for a malaria medicine designed for small infants, touted as an advance against a disease that takes hundreds of ...

Designation based on clinical evidence supporting potential of ianalumab in Sjögren's disease, including phase III trials1Distinction expedites development and review of treatments for serious conditi ...